Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | CHRNG | P07510 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740169 | 0.88 | HTR6 (0.42) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL6739874 | 0.81 | HTR6 (0.42) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL6741940 | 0.80 | HTR6 (0.40) | HTR6 | |
| SCHEMBL12090225 | 0.76 | CHRNB2 (0.62) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL6743248 | 0.74 | HTR6 (0.51) | HTR6 | |
| SCHEMBL6742324 | 0.74 | HTR6 (0.45) | HTR6 | |
| SCHEMBL6745791 | 0.74 | HTR6 (0.51) | HTR6 | |
| SCHEMBL6745125 | 0.73 | HTR6 (0.43) | HTR6 | |
| SCHEMBL6948541 | 0.73 | HTR6 (0.44) | HTR6 | |
| SCHEMBL6948549 | 0.73 | HTR6 (0.44) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | CHRNB2 50/4885CHRNB4 44/4885CHRNA3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.